Chimerix clinical trials

Acquired by Jazz Pharmaceuticals, Apr 21, 2025 · source ↗

The registry lists 33 studies whose lead sponsor is Chimerix. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 14, 2025.

Studies

Recruiting first, then most recently updated. Showing 33 of 33. All Jazz Pharmaceuticals studies →

• ONC201 in Pediatric H3 K27M GliomasTerminatedNCT03416530Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerTerminatedNCT03485729Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Oral ONC201 in Adult Recurrent GlioblastomaTerminatedNCT02525692Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Oral ONC201 in Relapsed/Refractory Multiple MyelomaTerminatedNCT02863991Phase 1/2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02873338Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid LeukemiaCompletedNCT02056782Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory FailureTerminatedNCT04389840Phase 2/3

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer PatientsTerminatedNCT01461915Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine GliomasNo longer availableNCT05392374

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy SubjectsCompletedNCT05391724Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant RecipientsCompletedNCT04285788

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade GliomasNo longer availableNCT03134131

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or DiseaseNo longer availableNCT02596997

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative SurgeryTerminatedNCT01161641Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPDTerminatedNCT00457951Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid LeukemiaCompletedNCT01843634Early Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• CMX001 in Post-transplant Patients With BK Virus ViruriaCompletedNCT00793598Phase 1/2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus InfectionCompletedNCT02087306Phase 3

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA VirusesCompletedNCT01143181Phase 3

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus DiseaseCompletedNCT01241344Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus ViremiaWithdrawnNCT03532035Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT RecipientsCompletedNCT01769170Phase 3

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of CytomegalovirusTerminatedNCT02439957Phase 3

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus DiseaseTerminatedNCT02439970Phase 3

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant RecipientsCompletedNCT00942305Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced CancerWithdrawnNCT02038699Phase 1/2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• The AdAPT Trial; Adenovirus After Allogeneic Pediatric TransplantationTerminatedNCT03339401Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of EbolaWithdrawnNCT04268966Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• The Chimerix CMX001 RegistryTerminatedNCT02167685

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304TerminatedNCT02420080

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus DiseaseWithdrawnNCT02271347Phase 2

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy VolunteersCompletedNCT01080820Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals

• Comparative Bioavailability and Effect of Food on CMX001 in Healthy VolunteersCompletedNCT00780182Phase 1

  Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals